Analyst firms · Oppenheimer · NRIX
Oppenheimer NRIX price target and rating history
Nurix Therapeutics Inc. (NRIX) · Health Care
Oppenheimer rates Nurix Therapeutics Inc. (NRIX) Outperform with a $28 price target, as of its latest action on Jun 29, 2026. It has published 3 rating actions on NRIX since February 2023, including 0 upgrades and 0 downgrades. Across 3 firms with a NRIX price target in the last 12 months, the median target is $30. Oppenheimer's $28 is 7% below that.
- Current rating
- Outperform
- Price target
- $28
- Median target, all firms
- $30
- Actions on NRIX
- 3
Oppenheimer price target on NRIX
Every Oppenheimer rating on NRIX
- Jun 29, 2026
- Jun 26, 2023
- Feb 28, 2023
How other firms rate NRIX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Oppenheimer | Outperform | $28 | Jun 29, 2026 |
| Morgan Stanley | Overweight | $36 | Jan 8, 2026 |
| Truist Securities | Buy | $30 | Nov 24, 2025 |
Questions about Oppenheimer and NRIX
- What is Oppenheimer's price target for NRIX?
- Oppenheimer's latest stated price target for Nurix Therapeutics Inc. (NRIX) is $28, from its action on Jun 29, 2026.
- What is Oppenheimer's rating on NRIX?
- Oppenheimer rates NRIX Outperform, a bullish rating, as of Jun 29, 2026.
- When did Oppenheimer last change its view on NRIX?
- On Jun 29, 2026, Oppenheimer resumes coverage at Outperform, price target $28.
- How does Oppenheimer's NRIX target compare with other analysts?
- Across 3 firms with a NRIX price target in the last 12 months, the median target is $30. Oppenheimer's $28 is 7% below that.
More NRIX rating histories
All Oppenheimer ratingsNRIX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.